Acetylcysteine zidrimer API Manufacturers

compare suppliers & get competitive offers

teaser-1024x654-1
No suppliers found
Sorry, there are currently no suppliers listed for this ingredient. Hopefully we can help you with other ingredients.
Notify me!
Want to be the first to find out when a supplier for Acetylcysteine zidrimer is listed?

Join our notification list by following this page.

List your company
Are you a supplier of Acetylcysteine zidrimer or other APIs and are you looking to list your company on Pharmaoffer?

Click the button below to find out more

Find CDMO
Looking for a CDMO/CMO that can help you with your pharmaceutical needs?

Click the button below to switch over to the contract services area of Pharmaoffer.

Looking for Acetylcysteine zidrimer API 2736440-65-4?

Description:
Here you will find a list of producers, manufacturers and distributors of Acetylcysteine zidrimer. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
API | Excipient name:
Acetylcysteine zidrimer 
Synonyms:
Dendrimer N-acetyl-cysteine , OP 101 , OP-101  
Cas Number:
2736440-65-4 
DrugBank number:
DB16496 
Unique Ingredient Identifier:
7JWF1EYH61

General Description:

Acetylcysteine zidrimer is a chemical compound identified by the CAS number 2736440-65-4.

Mechanism of Action:

Acetylcysteine zidrimer functions by: OP-101 is a novel compound that involves n-acetyl cyseine covalently bonded to an inactive dendrimer. In preclinical models, it was shown that OP-101 is selectively taken up by activated microglia, and localizes in areas wehre there is neuroinflammation. In these activated neural cells, OP-101 releases n-acetyl cysteine and helps reduce oxidative stress and inflammation. In multiple animal models, OP-101 was shown to normalize reactive macrophages, shut down cytokine cascades, and attenuate hyperinflammation. Thus, in May 2020, Orpheris, a subsidiary of Ashvattha Therapeutics and the developer of the compound, is pursuing a Phase 2 clinical study on the safety, pharmacokinetics, and efficacy of OP-101 in patients exhibiting severe COVID-19 symptoms (NCT04458298). This mechanism highlights the drug's role in inhibiting or promoting specific biological pathways, contributing to its therapeutic effects.

Categories:

Acetylcysteine zidrimer is categorized under the following therapeutic classes: Experimental Unapproved Treatments for COVID-19. These classifications highlight the drug's diverse therapeutic applications and its importance in treating various conditions.